Summary

Although clinical data suggest that the use of adjuvant radiation therapy (ART) following radical prostatectomy benefits both progression-free and overall survival, subgroups with adverse pathologic findings have been identified at high risk for treatment failure despite both surgery and ART. This article reports on results from RTOG 0621: Adjuvant 3DCRT/IMRT in Combination With Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial [NCT00528866].